Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 29, 2006

View Archived Issues

Snapshots of newly reported clinical trials in leukemia, myelodysplastic syndromes: II

Encouraging clinical, preclinical data on siplizumab presented

Beta-lactamase inhibitor NXL-104 enters phase I

Imvamune equally immunogenic in HIV-infected subjects as healthy subjects

Positive data for Nastech's PYY(3-36) nasal spray

MK-0457 begins pivotal phase II study in treatment-resistant advanced leukemias

Introgen obtains license to patent applications covering INGN-241 uses

Recordati and sigma-tau to comarket new antihypertensive drug in Italy

New phase II trial investigates SNS-595 in ovarian cancer

Positive preliminary data for Oxycyte in traumatic brain injury

Data finalized from phase II study of talabostat plus docetaxel in NSCLC

NIAID to study Emergent's group B streptococcus vaccine candidate

YM partners with TTY in Taiwan for tesmilifene in hepatic cancer

Labopharm files complete response to once-daily tramadol approvable letter

Topline phase I findings for AZ-003

Encouraging findings for CTCE-0214 in healthy volunteers

Intranasal PH-80 provides significant improvements in PMS symptoms

Volinanserin enhances the antidepressant effects of desipramine and tranylcypromine in rats

Otsuka granted Japanese rights to saxagliptin

Faropenem phase III trial stopped to consider exclusion of Ketek arm

New phase II trial studies XL-880 in patients with gastric cancer

Valeant sells HIV and cancer programs to Ardea

Cimzia shows positive effect on ACR scores in rheumatoid arthritis

Preliminary findings from three Telcyta phase III studies

Clinical efficacy and safety of bifeprunox reported in patients with acute and stable schizophrenia

Novel agents for transplant rejection revealed in recent patents

Compounds for possible use in anxiety, depression, etc., claimed in recent patents

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 3, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...